Delivery Order SPE2DB20D1004-SPE2DB23FF0Q2

Award Date 1/9/23
Potential Completion Date 1/10/23
Potential Value $1.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the delivery of DALIRESP 500 MCG TABLET 90S. The $12,620.07 firm fixed price delivery order has a completion date of March 13, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for providing a comprehensive range of pharmaceutical products and...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,118.73 firm fixed-price delivery order is for the supply of DALIRESP 500 MCG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of February 25, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,990.53 delivery order contract is for the supply of DALIRESP 500 MCG TABLET 90S, with a completion date of November 23, 2022. The contract has a firm fixed price pricing type and is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award, valued at $2,862.64, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the drug Daliresp 500 mcg Tablet 30s, with a period of performance through May 1, 2023. The contract is a firm fixed-price arrangement, with no set-aside designation indicated. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,908.26 firm-fixed-price delivery order is for the supply of DALIRESP 500 MCG TABLET 30S, a medical product, with a period of performance through March 2025. The award is not designated as a set-aside contract. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $15,938.14 firm fixed-price delivery order is for the supply of DALIRESP 500 MCG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of November 21, 2023 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,187.02 firm-fixed-price delivery order contract is for the supply of Daliresp 500 mcg tablets, a prescription medication. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, which provides a comprehensive range of...
This federal contract award was granted to Amerisourcebergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the U.S. government. The contract, valued at $21,357.35, is a Delivery Order with a Firm Fixed Price pricing type for the supply of DALIRESP 500 MCG TABLET 90S medication. The award was made by the Defense Logistics Agency (DLA) Troop Support Medical, a key agency within the Department of Defense (DoD) responsible for providing logistics, acquisition, and...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $1,401.58, is a Delivery Order with a Firm Fixed Price pricing type. It is not designated as a set-aside contract. The contract covers the supply of DALIRESP 500 MCG TABLET 90S, a pharmaceutical product, to support military healthcare programs. Amerisourcebergen holds a...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,476.34, is for the delivery of DALIRESP 500 MCG TABLET 30S, a prescription medication. The contract has an ultimate completion date of January 3, 2025 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant...
  • SPE2DB20D1004
    Indefinite Delivery Contract
  • SPE2DB20D1004-SPE2DB23FF0Q2
    Delivery Order

This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of Daliresp 500 mcg tablets. The $1,410.87 firm-fixed-price delivery order was issued by the Defense Logistics Agency (DLA) and has a completion date of January 10, 2023. The contract is not designated as a set-aside.

Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation through May 2024, covering similar medical products and prescription drugs.

Generated 2/27/25, 10:37 AM